IP Library Granted Patent US 11,369,647
Granted Patent B2
US 11,369,647 · App. 16/772,869 · Granted Jun 28, 2022

Probiotics for inhibiting and preventing progression of renal diseases, and compositions for inhibiting and preventing progression of renal diseases comprising same

Inventors: Su Ae Kim (Seongnam-si, KR); Chang Taek Oh (Seongnam-si, KR); Jong Hun Lee (Seongnam-si, KR); Su Hwan Lim (Seongnam-si, KR); Jeom Yong Kim (Seongnam-si, KR); Sun Kyu Park (Seongnam-si, KR); Min Jung Jang (Seongnam-si, KR); Min Ju Lim (Seongnam-si, KR)
Assignee: Green Cross Wellbeing Corporation
A61K35/747A23L33/135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,369,647
App. No.
16/772,869
Granted
Jun 28, 2022
Kind
B2
Abstract

A probiotic for inhibiting and preventing the progression of a renal disease and a composition containing the same are disclosed. The probiotic contains a novel Lactobacillus acidophilus BP105 strain, a novel Lactobacillus salivarius BP121 strain. The novel probiotics, the Lactobacillus acidophilus BP105 strain and the Lactobacillus salivarius BP121 strain exhibit excellent indoxyl sulfate removal ability, p-cresol removal ability, and phosphorus absorption ability.

Claims (6)

1. A method for inhibiting and preventing the progression of a renal disease in an animal, comprising administering a composition comprising one or more selected from the groups consisting of isolated Lactobacillus salivarius BP121 strain (Accession No. KCCM12170P), a culture thereof, a concentrate thereof, a paste thereof, a spray-dried material thereof, a lyophilisate thereof, a vacuum-dried material thereof, a drum-dried material thereof, a liquid thereof, and a dilution thereof, and a homogenate thereof in an effective amount to the animal, wherein the composition does not comprise a prebiotic inulin.

2. A method of claim 1 , wherein the method comprises further administering one or more selected from the groups consisting of isolated Lactobacillus acidophilus BP105 strain (Accession No. KCCM12169P), a culture thereof, a concentrate thereof, a paste thereof, a spray-dried material thereof, a lyophilisate thereof, a vacuum-dried material thereof, a drum-dried material thereof, a liquid thereof, a dilution thereof, and a homogenate thereof.

3. A method of claim 1 , wherein the Lactobacillus salivarius BP121 strain (Accession No. KCCM12170P) is isolated from feces of an infant.

4. A method of claim 1 , wherein the Lactobacillus salivarius BP121 strain (Accession No. KCCM12170P) has indoxyl sulfate removal ability, p-cresol removal ability, and phosphorus absorption ability.

5. A method of claim 1 , wherein the composition is a pharmaceutical composition, a dietary supplement, or a foodstuff.

6. A method of claim 1 , wherein the composition is a dietary supplement or a foodstuff.

Assignments (2)
CHANGE OF ADDRESS Recorded Dec 7, 2021
From: GREEN CROSS WELLBEING CORPORATION
To: GREEN CROSS WELLBEING CORPORATION
Reel/Frame 058357/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2020
From: KIM, SU AE; OH, CHANG TAEK; LEE, JONG HUN; LIM, SU HWAN; KIM, JEOM YONG; PARK, SUN KYU; JANG, MIN JUNG; LIM, MIN JU
To: GREEN CROSS WELLBEING CORPORATION
Reel/Frame 052937/0427 →
Priority Claims (1)
KR 10-2017-0173590 · Dec 15, 2017 · national
Continuity (1)
Related Publication 20210169951A1 · Jun 10, 2021